2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Gene Editing, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Quality of Care, Diseases, Immunology, Autoimmune Disorders, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

1227 Dexamethasone, ruxolitinib, and high-dose vitamin C (VC+Ru+D) regimen as a bridge to definitive therapy for EBV-associated hemophagocytic lymphohistiocytosis

Wu Shishuang, MD, Jun Zhu2, Bo Lv3, Jiayi Ren4, Yuting Tao5, Fengxuan Zhang6, Kai Qing7, Kai Xue, MD8
1 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Liquan Hospital, Shanghai, China
3 Shanghai Liquan Hospital, Shanghai, China
4 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 Shanghai Liquan Hospital, Shanghai, China
6 The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China
7 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Background: Epstein–Barr virus (EBV) is the most prevalent trigger of infection-associated hemophagocytic lymphohistiocytosis (HLH) in East Asia. Standard etoposide-based protocols (HLH-94, HLH-2004) yield 2-month response rates of around 50% and are limited by myelosuppression and hepatotoxicity in patients already compromised by hyperinflammation. The ruxolitinib-dexamethasone (Ru-D) backbone achieved a 2-month overall response rate (ORR) of 85.7% in newly diagnosed HLH (Zhou et al, Blood 2025), and our previous work showed that high-dose vitamin C, which kills EBV-positive B cells in vitro, was associated with improved early survival (Ren et al, ASH 2025). We therefore evaluated the chemo-free regimen of dexamethasone, ruxolitinib, and high-dose vitamin C (VC+Ru+D) as cytokine storm control and a bridge to definitive therapy for EBV-HLH patients.

Methods: We conducted a single-center retrospective cohort study at Ruijin Hospital, Shanghai (2024–2026), evaluating VC+Ru+D (dexamethasone 10 mg/m²/day, ruxolitinib 10 mg twice daily, and intravenous vitamin C 200 mg/kg/day) in 29 consecutive EBV-HLH patients confirmed by plasma or tissue EBV-DNA or metagenomic next-generation sequencing. The primary endpoint was day-28 ORR, defined as the percentage of patients with complete response (CR), partial response (PR), or improvement in HLH measures, consistent with Zhou et al. For secondary endpoints, we compared paired D0–D4 laboratory changes with the Wilcoxon signed-rank test (nominal two-sided P values, unadjusted for multiplicity). We analyzed overall survival from treatment initiation and recorded bridging to definitive therapy.

Results: The median age was 48 years (range 21–73), and 69% were male; all patients were newly diagnosed and treatment-naïve, receiving VC+Ru+D as first-line therapy. Paired D0/D4 data were available for all 29 patients. Platelet count (66→86×10?/L, +30.3%, P=0.009), soluble CD25 (3,713→1,982 pg/mL, −46.6%, P=0.037), and fibrinogen (1.5→1.6 g/L, +6.7%, P=0.027) improved significantly. Hemoglobin decreased (88.5→73.5 g/L, −16.9%, P=0.016), consistent with ruxolitinib-associated anemia. Other parameters including ferritin, transaminases, white blood cell count, triglycerides, and total bilirubin remained stable. At day 28, 26 of 29 patients achieved partial response (ORR 89.7%); three patients had no response, including one who died before assessment. No patient achieved CR, consistent with the anti-inflammatory regimen that controls the cytokine storm without eradicating the underlying EBV reservoir; persistent viral replication sustains residual HLH activity, so durable complete remission requires subsequent definitive therapy targeting the EBV-driven process. As a bridge, 11 patients (37.9%) proceeded to allo-HSCT, while most others transitioned to DEP-based regimens. With a median follow-up of 7.3 months (range 3.9–16.6), 11 deaths occurred (37.9%): one within 28 days of treatment initiation; four after day 28 in patients not bridged to transplantation; four during transplantation; and two more than one month after transplantation. The safety profile was dominated by cytopenias (anemia 97%, leukopenia 83%, thrombocytopenia 76%) and infection (83%, grade ≥3 in 79%), consistent with the underlying severity of EBV-HLH. No unexpected treatment-related adverse events emerged.

Conclusions: VC+Ru+D achieved an 89.7% day-28 ORR with a manageable safety profile in EBV-HLH, although complete responses were not expected without eradication of the EBV reservoir. This triple regimen offers a chemotherapy-sparing path to definitive therapy when etoposide is contraindicated or as a bridge to definitive therapy. Prospective multicenter evaluation is warranted.

Wu Shishuang, MD: No relevant conflicts of interest to declare.